ERBB2 and melanoma: Moreover, pharmacologic inhibition of HER2 kinase activity using the irreversible HER2 kinase inhibitor canertinib in HER2-overexpressing cells (Fig. 5D) or using trastuzumab (preventing HER2 dimerization and considered to be a reversible inhibitor for HER2 activation) in invasive melanoma cells lowered MT dynamics (Fig. 5E), together indicating that HER2 is involved in increasing MT growth rates in melanoma cells.